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Purpose or Objective: To report the outcome of localized 
gastric lymphoma treated with radiation therapy. 
 
Material and Methods: This study included 27 patients (14 
men, 13 women; median age 67 years, range 37 – 83 years) 
with localized gastric lymphoma and who received radiation 
therapy between January 2005 and December 2014 at our 
institution. Patients with a follow-up period < 6 months were 
excluded. Twenty-three patients were mucosa-associated 
lymphoid tissue (MALT) lymphoma, and 4 patients were 
diffuse large B-cell lymphoma (DLBCL). The stage was 
classified by Lugano international conference classification. 
All patients with MALT lymphoma were Stage Ⅰ. In DLBCL, 2 
patients were Stage Ⅰ, and 2 patients were Stage Ⅱ1. The 
median radiation dose in MALT lymphoma was 30Gy (range, 
7.5–30), and in DLBCL was 40.5Gy (range, 30–40.5). All MALT 
lymphoma patients with Helicobacter pylori-positive were 
received eradication therapy before radiation therapy. All 
patients with DLBCL were treated with chemotherapy 
followed by radiation therapy. Acute and late adverse events 
were evaluated in accordance with Common terminology 
criteria for adverse events, version 4.0. The local recurrence 
rate was calculated using Kaplan-Meier analysis. 
 
Results: The median follow-up period was 58 months (range, 
6.0–120.0). Local recurrence occurred in only 2 patients with 
MALT lymphoma. No distant recurrence was observed. Local 
recurrence rate in MALT lymphoma was 91% at 1 year, 91% at 
3 years. In acute adverse events, 5 patients had grade 3 
white blood cell decreased, 1 patient had grade 4 white 
blood cell decreased and platelet count decreased, and 1 
patient had grade 3 anorexia. One patient with MALT 
lymphoma could not achieve the planned radiation therapy 
because of grade 4 white blood cell decreased and platelet 
count decreased. There was no grade 3 or greater late 
adverse events. One patient with MALT lymphoma suffered 
from gastric cancer, and underwent endoscopic excision. No 
patients died of gastric lymphoma. One patient died of lung 
cancer. 
 
Conclusion: Radiation therapy for localized gastric lymphoma 
was safe and effective. Our result was similar to previous 
reports. 
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Purpose or Objective: Radiation therapy (RT) is an important 
component of therapy for patients with Hodgkin (HL) and non 
Hodgkin lymphomas (NHL).  
In our retrospective analyze we showed the role of 
radiotherapy in treatment of lymphomas and its influence on 
disease free (DFS) and overall survival (OS) of patients. 
 
Material and Methods: From 2000 to 2010, we treated 347 
patients (pts) with lymphomas (Hodgkin - 286 and non 
Hodgkin - 61). There were 24 pts with stage I, 186 with stage 
II, 40 with stage III and 36 pts with stage IV of Hodgkin 
lymphoma. Among group of pts with non Hodgkin lymphoma 
there were 20 pts with stage I, 17 with stage II, 7 with stage 
III and 17 pts with stage IV. Sixty-nine percent of pts had 
favorable HL and 81% of pts nodular sclerosis as histological 
type. Sixty-four percent of pts with NHL had aggressive 
disease. Three dimensional conformal radiotherapy has been 
planned by computed tomography (CT) alone or by 18-FDG 
positron emission tomography/CT (18-FDG PET/CT). Mostly, 
patients received chemotherapy (95%) before RT. However, 
67% of pts with NHL did not receive rituximab.Whole group of 
our pts have been irradiated by involved field radiotherapy 
(IFRT). Most of patients received 36Gy (1.8-2Gy daily) (71%) 
and 29% more than 36Gy, in both groups. 
 
Results: Median follow-up time was 8 years. Among patients 
with HL, 33 pts (12%) had relapse and 11 pts (18%) with NHL. 
Relapses occur most often outside of irradiated volume in 
both groups of pts. Twenty five percent with HL patients had 
toxicity, most commonly pulmonary and 7% pts with NHL. 
During the median time of 13.5 years the incidence of a 
secondary malignancies (SM) was 3% in pts with HL and 2% 
with NHL. In group who had HL 91% of these pts lived and 74% 
in group with NHL. Ten-years DFS was 89% (HL) and 74% (NHL) 
and 10-years OS was 91% (HL) and 82% (NHL). 
 
Conclusion: Radiotherapy had an important place in the 
treatment of our patients with HL, as well as in a group of 
NHL with acceptable toxicity and incidence of secondary 
malignancies. 
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Purpose or Objective: To assess the incidence of second 
cancer in a mono-institutional cohort of long-time surviving 
Primary Mediastinal B Cell Lymphoma (PMBCL) patients 
treated with combined radio-chemo-immunotherapy. 
 
Material and Methods: Between 1991 and December 2006, 
107 consecutive untreated patients (pts) with PMBCL were 
treated at our Departments. Ninety-two/107 pts were 
evaluable for the second cancer incidence. All patients were 
treated with standard Methotrexate, Adriamycin, 
Cyclophosphamide, Vincristine, Prednisone and Bleomycin 
(MACOP-B) ± Rituximab; all patients underwent mediastinal 
radiation therapy (RT) at a dose of 30-36 Gy. 
 
Results: At the end of combined treatment, the overall 
response rate (ORR) including CR+Cru/PR was 91.3% while 7 
(7.6 %) patients showed progressive disease. Nine/84 (9.7%) 
patients relapsed within 10 months (range 3-10 months) from 
the end of therapy. After a median follow-up of 142 months 
(1-212 months), the actuarial 15-year OS and PFS were 87% 
and 84%, respectively. We recorded secondary malignancies 
in 3/80 long-surviving patients (3.75%) with cumulative 
incidence of thyroid and A acute myeloid leukemia of 3.47 at 
15 years and with a 20-year second cancer-free survival of 
82%. We observed 2 papillary thyroid cancers with a 
Standardized Incidence Ratio of 7.97 and with an Absolute 
Excess Risk of 17. 84. Moreover, we observed 1 Acute Myeloid 
Leukemia ( AML) versus 0.015 expected cases with a SIR of 
66.53 and with an AER of 10.05. No breast cancer occurred  
 
Conclusion: Combined modality treatment of chemotherapy± 
with/without Rituximab and mediastinal RT was related to a 
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statistically significant SIR and AER for thyroid cancer and 
acute myeloid leukemia.  
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Purpose or Objective: Despite the use of RT before or after 
salvage haemopoeitic stem cell transplant for relapsed and 
refractory lymphoma, the indications, timing and benefit of 
radiotherapy are not well established and it is unlikely that 
these questions will be tested in a randomised study. We 
present the outcomes of a retrospective analysis of the 
benefit of radiotherapy given before or after HSCT for 
lymphoma.  
 
Material and Methods: We reviewed our transplant and 
radiotherapy databases to identify patients. Inclusion criteria 
were patients who underwent HSCT from 2004-2010 for 
refractory or relapsed lymphoma. Primary end point was 
progression-free survival (PFS) and secondary end point was 
overall survival (OS). Risk of relapse and death was compared 
for those who received radiotherapy and those who did not 
using Cox’ proportional hazards ratio using age at diagnosis as 
an independent predictor. Rates of death were analysed 
using Fisher’s exact test. 
 
Results: We identified 330 patients who underwent HSCT 
from 2004-2010 for relapsed lymphoma.72 patients had 
Hodgkins’s and 258 patients had non-Hodgkin’s lymphoma. 
The median age at diagnosis was 46.5 years (14.6-72 years). 
The median age at transplant was 50.6 years (17.4-73.2 
years). 121 patients (36%) underwent an allogeneic and 209 
patients (64%) underwent an autologous transplant. Median 
follow-up was 1.8 years (0.0-10.0 years).  
94 patients (28%) underwent radical RT before or after 
transplant (excluding TBI). 58 patients underwent 
radiotherapy before HSCT and 36 subsequent to HSCT. Of 
those who underwent RT before HSCT 64% were in remission 
going to HSCT compared with 75% of those who received RT 
after HSCT. There was a trend towards a shorter PFS for 
those who did not receive RT (HR1.72, 95% CI 0.96-3.67). 
There was no difference in mortality at 3 years between the 
two groups (p=0.78). There was no difference in OS between 
the two groups (HR=0.98, 95% 0.67-1.56). We are currently 
analysing the pattern of relapse and the impact of different 
variables on relapse and overall survival. 
 
Conclusion: Peri-transplant RT seems to offer a progression 
free survival benefit in patients with relapsed/refractory 
lymphoma undergoing HSCT although confirmation is 
required. 
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Purpose or Objective: Splenic irradiation has been used as 
first treatment for several hematological neoplasm, including 
chronic leukemia or myeloid malignancies, but with the 
availability of new drugs its application was restricted. In 
selected cases, not only with palliative intentions, irradiation 
can be useful treatment modality 
Material and Methods: Our study included 11 patients: 5 with 
chronic lymphocytic leukemia, 5 with high-grade B-cell 
lymphoma and 1 with diagnose of polycythaemia Vera. In 5 
patients the treatment was with radical intention (all of 
them with high grade lymphoma) and the rest were 
palliatives as treatment of pain or normalization of red blood 
cell that allows more time between transfusions. The doses 
were generally low with range between 5 and 10 Gy in 0.5Gy 
daily fractions because doses higher than 10Gy did not 
provide benefits according to literature.  
 
Results: We got 5 complete responses confirmed by PET but 
after 2 years 2 of them relapsed and were treated with 
radiotherapy again with the same scheme and obtain the 
same response to the present day. In terms of palliative 
intention, splenic irradiation provided a relief of pail from 6 
to 12 months, and in 4 patients the disease progressed 
without new splenic symptoms. One patient received 3 
courses of radiotherapy for painful splenomegaly with a gap 
of 12, 9 and 6 months without acute toxicity and died due to 
non-splenic leukemia progression.  
 
Conclusion: In selected patients who are not responsive, not 
suitable for systemic treatment or palliatives, splenic 
irradiation can be an efficient therapy with little toxicity and 
sustained response over time. f of pail from 6 to 12 months, 
and in 4 patients the disease progressed without new splenic 
symptoms. One patient received 3 courses of radiotherapy for 
painful splenomegaly with a gap of 12, 9 and 6 months 
without acute toxicity and died due to non-splenic leukemia 
progression.  
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Purpose or Objective: We evaluated the tumor response and 
clinical outcomes according to molecular subtypes in locally 
advanced breast cancer patient who received neo-adjuvant 
chemotherapy (NAC) followed by surgery and radiotherapy. 
 
Material and Methods: We retrospectively reviewed 400 
patients with clinical stage II-III breast cancer who received 
NAC followed by surgery and radiotherapy in Samsung Medical 
Center, between 2007 and 2011. Among these, 329 patients 
who completed recommended therapy were analyzed on 
clinical outcomes and prognostic factors, with focusing on 
the molecular subtypes. Luminal A and B, HER2-enriched, and 
triple-negative subgroups were identified according to the 
hormone receptor (ER and PR), HER2, and Ki-67 receptor 
status. 
 
Results: Overall pathologic complete response (pCR) rate 
after NAC were 20.1% and HER2- enriched subgroup was 
associated with the highest rates of pCR (43.6%), whereas 
luminal A showed the lowest rates of pCR (4.6%). A 
significant correlation was found between pathologic 
response (pCR vs. non-pCR) and molecular subtypes (p value 
<0.001). The median follow-up duration was 55 months 
(range, 5 to 98 months). The 5-year overall survival (OS) and 
disease-free survival (DFS) rates were 88.9% and 72.9%, 
respectively. In subgroup analysis, according to the 
pathologic response (pCR vs. non-pCR), triple-negative 
subtype proved significant difference in 5-year OS rate 
(100.0% vs. 71.6%, p value =0.005) and 5-year DFS rate (93.1% 
vs. 55.1%, p value <0.001). HER2-enriched subtype also 
showed significant difference in 5-year OS rate (100.0% vs. 
79.1%, p value =0.05). A distinct survival difference according 
to molecular subtypes was found especially in non-pCR group 
(5-year OS and DFS, p value <0.001, respectively), in 
contrast, pCR group did not show a statistical difference of 
survival according to molecular subtypes. When compared 
